Table 3.
Treatment response rates at week 12 in patients in the full analysis set with nonresponder imputationa
| Response at week 12 | Adalimumab 40 mg SC every other week (n = 56) | ABT‐122 60 mg SC every other week (n = 55) | ABT‐122 120 mg SC every other week (n = 56) | ABT‐122 120 mg SC every week (n = 55) |
|---|---|---|---|---|
| ACR20 | 38 (67.9) | 34 (61.8) | 42 (75.0) | 44 (80.0) |
| ACR50 | 27 (48.2) | 19 (34.5) | 26 (46.4) | 26 (47.3) |
| ACR70 | 12 (21.4) | 12 (21.8) | 10 (17.9) | 20 (36.4) |
| DAS28‐hsCRP <3.2 | 25 (44.6) | 18 (32.7) | 29 (51.8) | 30 (54.5) |
| DAS28‐hsCRP <2.6 | 17 (30.4) | 12 (21.8) | 21 (37.5) | 23 (41.8) |
| CDAI ≤10 | 22 (39.3) | 18 (32.7) | 24 (42.9) | 30 (54.5) |
| CDAI ≤2.8 | 4 (7.1) | 4 (7.3) | 6 (10.7) | 6 (10.9) |
a
Values are the number (%) of responders based on the American College of Rheumatology response criteria for improvement of 20% (ACR20), 50% (ACR50), and 70% (ACR70), 2 different cutoffs for scores on the Clinical Disease Activity Index (CDAI), and 2 different cutoffs for scores on the Disease Activity Score in 28 joints using high‐sensitivity C‐reactive protein level (DAS28‐hsCRP). SC = subcutaneous.